Tesamorelin 10mg

Tesamorelin, also known as Egrifta, is a pharmaceutical-grade synthetic peptide that mimics the naturally occurring Growth Hormone-Releasing Hormone (GHRH). This investigational compound functions by binding to and activating GHRH receptors in the anterior pituitary gland, leading to a pulsatile release of endogenous growth hormone (GH). Research applications for Tesamorelin primarily focus on its potential to modulate body composition, particularly in conditions characterized by excess visceral adipose tissue. Studies have explored its effects on lipolysis, insulin sensitivity, and overall metabolic profiles, making it a valuable tool for endocrinology and metabolic research. For optimal research integrity, Tesamorelin should be handled with meticulous care in a controlled laboratory environment. Researchers should wear appropriate personal protective equipment, including gloves and eye protection, to prevent direct contact. It is imperative to reconstitute the lyophilized peptide using sterile bacteriostatic water, following precise volumetric measurements to ensure accurate solution concentration. Avoid vigorous shaking during reconstitution to prevent peptide degradation. All research protocols involving Tesamorelin must adhere to institutional guidelines and ethical considerations for experimental compounds. Proper storage is critical to maintain the stability and efficacy of Tesamorelin. The lyophilized powder should be stored long-term at -20°C or colder, protected from light and moisture. Once reconstituted, the solution should be refrigerated at 2-8°C and used within a specified timeframe, typically no more than 14-21 days, to prevent degradation. Repeated freeze-thaw cycles should be strictly avoided. Ensure the vial is tightly sealed to prevent contamination and evaporation. This product is strictly for research purposes and not for human consumption.